News Releases

Study Designed to Evaluate the Use of Apixaban in On-X Aortic Valve Patients ATLANTA , May 7, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY) , a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has initiated enrollment in the PROACT Xa clinical trial,

ATLANTA , April 30, 2020 /PRNewswire/ -- First Quarter and Recent Business Highlights: Achieved total revenues of $66.4 million in the first quarter 2020 versus preliminary first quarter 2020 revenues of $65.5 million Total revenues decreased 2% and decreased 1% on a constant currency basis versus

ATLANTA , April 16, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2020 first quarter financial results will be released on Thursday, April 30, 2020 after the market closes.  On that day, the Company

ATLANTA , April 1, 2020 /PRNewswire/ --  CryoLife, Inc. (NYSE: CRY) , a leading cardiac and vascular surgery company focused on aortic disease, announced today it has taken multiple steps to focus on the health and welfare of its employees, patients, and customers.

Newest Hybrid Stent Graft Offering Enhances Ease-of-Use ATLANTA , March 4, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has received CE Mark for the E-vita Open NEO , a hybrid stent graft system

ATLANTA , Feb. 27, 2020 /PRNewswire/ --  CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today it has received CE Mark for the On-X Ascending Aortic Prosthesis (AAP), allowing resumed distribution in the European Union .  The On-X AAP

ATLANTA , Feb. 13, 2020 /PRNewswire/ -- Fourth Quarter and Recent Business Highlights: Total revenues were $69.7 million in the fourth quarter of 2019, reflecting year over year growth of 3% and a 4% increase on a non-GAAP constant currency basis, both compared to the fourth quarter of 2018 On-X ®

ATLANTA , Jan. 30, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2019 fourth quarter and year-end financial results will be released on Thursday, February 13, 2020 after the market closes.  On that

Study Designed to Evaluate the Use of Apixaban in On-X Aortic Valve Patients ATLANTA , Dec. 23, 2019 /PRNewswire/ --  CryoLife, Inc. (NYSE: CRY) , a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has received authorization from the U.S.

CryoLife Will Supply NeoPatch, a Chorioamniotic Membrane Tissue, to Misonix ATLANTA , Dec. 19, 2019 /PRNewswire/ --   CryoLife, Inc. (" CryoLife "; NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has entered into an agreement whereby